Buzz Stocks: Merck & Co, Bristol-Myers Squibb, BlackBerry

Today's stocks to watch in the news include MRK, BMY, and BBRY

Dec 8, 2014 at 9:16 AM
facebook twitter linkedin


Futures are pointed lower this morning, as traders digest disappointing economic data from overseas. Back on the homefront, specific equities in focus are pharmaceutical firms Merck & Co., Inc. (NYSE:MRK) and Bristol-Myers Squibb Co (NYSE:BMY), as well as smartphone maker BlackBerry Ltd (NASDAQ:BBRY).

  • MRK has agreed to purchase Cubist Pharmaceuticals Inc (NASDAQ:CBST) for $8.4 billion, or $102 per share, with the former assuming all of the latter's $1.1 billion in debt. On the charts, Merck & Co., Inc. has tacked on nearly 23% this year, and tagged an 11-year peak of $61.77 on Friday, before settling at $61.49. Short-term speculators, meanwhile, have shown a preference for puts over calls, as evidenced by the security's Schaeffer's put/call open interest ratio (SOIR) of 1.26, which ranks just 7 percentage points below a 52-week peak. Ahead of the bell, MRK is 0.2% lower, while CBST has surged 36%.

  • After closing Friday at $60.65 -- up almost 28% from its mid-October low of $47.54 -- BMY has tacked on 0.3% in pre-market trading. This comes after the company said its lymphoma drug, nivolumab, showed promise in an early stage trial. Should the stock continue its positive momentum, a round of upgrades and/or price-target hikes could help propel Bristol-Myers Squibb Co higher. Of the 17 analysts currently covering the outperforming equity, eight maintain a "hold" or "strong sell" recommendation. Plus, the consensus 12-month price target of $56.58 stands at a discount to present trading levels.

  • BBRY is up 2% ahead of the bell -- poised to add to its roughly 44% year-to-date advance -- after the firm launched a new cancer genome browser with health care data provider NantHealth. The browser is fully encrypted, and allows doctors to access patient information on the BlackBerry Passport. Despite BlackBerry Ltd's impressive technical showing, the stock is surrounded by skeptics. Short interest, for example, accounts for almost 21% of the stock's available float, representing nearly six sessions' worth of pent-up buying demand, at typical daily trading levels. Elsewhere, 95% of covering analysts maintain a "hold" or worse suggestion, and the average 12-month price target of $10.83 is just a chip-shot away from Friday's close at $10.68. An unwinding of this bearish sentiment could translate into a fresh burst of buying power.
 

 

 

These investors are using the market's volatility to their advantage and scoring triple-digit gains on many of their trades.

Even in today's sideways bear market, this trading strategy has continued to provide consistency and profitability to a small group of investors. By using this approach, these traders are removing directional risk and still hitting triple-digit returns. If you want access to this strategy, and lower risk with higher returns sounds good to you, then don't wait another minute.

Join us now to receive our next trades the moment they come out!

 

Common mistakes options traders make
 


 


 
Special Offers from Schaeffer's Trading Partners